Mark G. Edwards Purchases 30,000 Shares of AcelRx Pharmaceuticals, Inc. (ACRX) Stock
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Director Mark G. Edwards bought 30,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were bought at an average cost of $1.90 per share, for a total transaction of $57,000.00. Following the transaction, the director now owns 150,000 shares in the company, valued at approximately $285,000. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
AcelRx Pharmaceuticals, Inc. (NASDAQ ACRX) traded up $0.03 on Friday, reaching $2.08. The company had a trading volume of 687,124 shares, compared to its average volume of 1,004,681. AcelRx Pharmaceuticals, Inc. has a one year low of $1.55 and a one year high of $5.75. The company has a debt-to-equity ratio of -0.43, a current ratio of 4.78 and a quick ratio of 4.71.
TRADEMARK VIOLATION WARNING: “Mark G. Edwards Purchases 30,000 Shares of AcelRx Pharmaceuticals, Inc. (ACRX) Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/18/mark-g-edwards-purchases-30000-shares-of-acelrx-pharmaceuticals-inc-acrx-stock.html.
Several equities analysts have recently weighed in on the company. Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 1st. ValuEngine raised AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. Zacks Investment Research raised AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Jefferies Group LLC downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 13th. Finally, Roth Capital reissued a “buy” rating and set a $12.50 target price on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $6.83.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.